<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164578</url>
  </required_header>
  <id_info>
    <org_study_id>MicroVasc-DIVA</org_study_id>
    <nct_id>NCT02164578</nct_id>
  </id_info>
  <brief_title>Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease</brief_title>
  <acronym>MicroVasc-DIVA</acronym>
  <official_title>Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to
      low dose aspirin in type 2 diabetic patients.

      Especially patients with cardiovascular disease and subclinical inflammation are in the focus
      of interest.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>forearm blood flow</measure>
    <time_frame>20 weeks</time_frame>
    <description>Difference of change of forearm blood flow with venous occlusion plethysmography at baseline and after forearm ischemia after 20 weeks treatment between rivaroxaban and aspirin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laserdopplerfluxmetry (LDF)</measure>
    <time_frame>20 weeks</time_frame>
    <description>change of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobilography</measure>
    <time_frame>20 weeks</time_frame>
    <description>Measurement of arterial stiffness measured by Mobilograph (IEM Inc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite laboratory measurement</measure>
    <time_frame>20 weeks</time_frame>
    <description>composit laboratory markers for endothelial function,
composite of biomarkers of inflammation
bleeding side effects
composite laboratory metabolic marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Type 2 Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive IMP in 5mg b.i.d. for 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive IMP in a dosage of 100mg once daily for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes duration between 2 and 20 years

          -  documented atherosclerotic CVD:

          -  major cardiovascular event in medical history or

          -  coronary angiography showing a coronary artery stenosis of &gt; 50 % or

          -  carotid ultrasound showing an IMT &gt; 1 mm and plaque of carotid artery or

          -  left ventricular hypertrophy or

          -  macroalbuminuria in the absence of other renal diseases

          -  increased hsCRP (&gt; 2 mg/l but &lt; 10 mg/l) and/or increased PAI 1 (&gt; 15 ng/ml)

          -  stable treatment with statins (if tolerated)

          -  age 40 - 75 years

        Exclusion Criteria:

          -  CV event with need for oral anticoagulation or dual platelet inhibitor therapy or
             acute coronary syndrome &lt; 12 month before study entry

          -  sustained uncontrolled hypertension: systolic bp &gt; 180 mmHg or diastolic bp &gt; 100 mmHg

          -  hypersensitivity to the active substance

          -  active clinically significant bleeding

          -  significant risks for major bleeding

          -  concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke
             or a transient ischaemic attack (TIA)

          -  hepatic disease associated with coagulopathy and clinically relevant bleeding risk

          -  chronic renal failure with eGFR &lt; 15 ml/min (MDRD formula)

          -  Pregnant or breast-feeding woman and woman without adequate method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Pistrosch, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GWT-TUD GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carsta Köhler, Dr. rer. medic.</last_name>
    <phone>0049 351</phone>
    <phone_ext>25933190</phone_ext>
    <email>carsta.koehler@gwtonline.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin / Charité Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Schaper/ Dr. Faulmann</name>
      <address>
        <city>Dresden</city>
        <zip>01279</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Schaper, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH / Studienzentrum Hanefeld</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Pistrosch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiologicum Prina</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

